As director, Dr. Wegrzyn will oversee ARPA-H’s research portfolio and budget, according to a Sept. 12 statement from the White House.
“I am deeply honored to have the opportunity to shape ARPA-H’s ambitious mission and foster a vision and approach that will improve health outcomes for the American people, including President Biden’s Cancer Moonshot,” Dr. Wegrzyn said.
Dr. Wegrzyn is currently the vice president for business development at Ginkgo Bioworks, a biotech company focused on cell programming. She is the former program manager of the biological technologies office of the Defense Advanced Research Projects Agency, one of the institutions that inspired ARPA-H.
At Becker's 4th Annual CEO + CFO Roundtable, taking place November 2–5 in Chicago, more than 1,500 hospital and health system executives tackle decisions that determine whether organizations thrive or merely survive: protecting margins under cost pressure, choosing where to grow, renegotiating payer relationships, stabilizing the workforce and proving real ROI on technology. This is where leaders work through them together, face-to-face. Apply for complimentary registration now.
